A5038925165- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Glioma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Melanoma and MAPK Pathways
- Medical Imaging Techniques and Applications
- Brain Metastases and Treatment
- Nuclear Structure and Function
- Radiation Therapy and Dosimetry
- Brain Tumor Detection and Classification
- Colorectal Cancer Treatments and Studies
- Functional Brain Connectivity Studies
- Advanced Radiotherapy Techniques
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- CRISPR and Genetic Engineering
- Lung Cancer Treatments and Mutations
- Optical Imaging and Spectroscopy Techniques
- Meningioma and schwannoma management
- Advancements in Semiconductor Devices and Circuit Design
Aalborg University Hospital
2015-2025
Nordic Society of Gynecologic Oncology
2024-2025
Copenhagen University Hospital
2023
Faculty (United Kingdom)
2016
Abstract Background An increasing number of trials indicate that treatment outcomes in cancer patients with metastatic disease are improved when targeted treatments matched druggable genomic alterations individual (pts). estimated 30–80% advanced solid tumors harbor actionable alterations. However, the efficacy personalized is still scarcely investigated larger, controlled due to low frequency and heterogenous distribution among different histologic tumor types. Therefore, overall effect on...
BackgroundMetastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless tumor PD-L1 expression.MethodsWe conducted population-based study including all patients MM (except ocular melanoma) first-line therapy or anti-PD-1 monotherapy since January 2017. Baseline data known prognostic characteristics were used in multivariable propensity-matched score (PMS) analyses to assess progression-free survival (PFS), melanoma-specific (MSS), overall (OS)...
Treatment with immune checkpoint inhibitors (ICI) has expanded into the adjuvant setting enhancing importance of knowledge on immune-related toxicities and their impact health-related quality life (HRQoL). Large phase 3 trials patients resected Stage III/IV melanoma found no effect HRQoL during immunotherapy. This study investigates how was affected after immunotherapy in a real-world setting.Patients treated nivolumab from 2018 to 2021 Denmark were identified using Danish Metastatic...
BackgroundClinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions.MethodsObservational population-based study examining a national cohort of stage III-IV melanoma referred therapy. Data were extracted from the Danish Metastatic Melanoma Database (DAMMED).ResultsBetween November 2018 January 2022, 785 received anti-PD-1. The majority had III...
In a per-protocol analysis of molecularly profiled patients with treatment-refractory, end-stage cancer discussed at the National Molecular Tumor Board (NMTB), we aimed to assess overall survival (OS) outcome targeted treatment compared no treatment.
<p>Supplementary Material</p>
<p>All identified pathogenic variants in the samples analyzed.</p>
<h3>Introduction/Background</h3> Primary results from the ENGOT-OV16/NOVA study showed that niraparib maintenance therapy significantly prolonged progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of germline BRCA (gBRCA) mutation or homologous recombination deficiency (HRD) biomarker status. Here we report updated final overall (OS) and long-term safety results. <h3>Methodology</h3> NOVA was a randomised, double-blind,...
The Danish Neuro Oncology Group (DNOG) has established national consensus guidelines for the delineation of organs at risk (OAR) structures based on published literature. This study was conducted to finalise these and evaluate inter-observer variability delineated OAR by expert observers.The DNOG were formed participants from all centres that treat brain tumours with radiotherapy. In a two-day workshop, discussed finalised pilot study. Following this, ten contoured following OARs T1-weighted...
The introduction of modern therapies improved the median survival patients with metastatic melanoma (MM). Here, we determined real-world impact treatments on long-term MM.In a population-based study, extracted all cases MM diagnosed in four non-consecutive years marked by major changes available 1st line (2012, 2014, 2016, and 2018) from Danish Database. Patients were grouped into "trial-like" "trial-excluded" based common trial eligibility criteria.We observed sustained 2016 or 2018,...
Our goal was to describe a precision medicine program in regional academic hospital, characterize features of included patients and present early data on clinical impact.We prospectively 163 eligible with late-stage cancer any diagnosis from June 2020 May 2022 the Proseq Cancer trial. Molecular profiling new or fresh frozen tumor biopsies done by WES RNAseq parallel sequencing non-tumoral DNA as individual reference. Cases were presented at National Tumor Board (NMTB) for discussion targeted...
Patients with lower-grade gliomas are long-term survivors after radiotherapy and may benefit from the reduced dose to normal tissue achievable proton therapy. Here, we aimed quantify differences in uninvolved brain contralateral hippocampus compare risk of radiation-induced secondary cancer for photon plans glioma patients.Twenty-three patients were included this in-silico planning comparative study had calculated (50.4 Gy(RBE = 1.1), 28 Fx) applying similar constraints target organs at...
Abstract Background This Danish cohort study aims to (1) compare patterns of care (POC) and survival patients with multifocal glioblastoma (mGBM) those unifocal (uGBM), (2) explore the association patient-related factors treatment assignment prognosis, respectively, in subgroup mGBM patients. Methods Data on all adults newly diagnosed, pathology-confirmed GBM between 2015 2019 were extracted from Neuro-Oncology Registry. To POC uGBM, we applied multivariable logistic Cox regression analysis,...
Abstract Purpose Immune-related thyroid adverse events (irTAEs) occur frequently following immune checkpoint inhibitor (ICI) therapy. The purpose of this study is to provide knowledge about the incidence, clinical timeline characteristics, associated factors irTAEs, and potential impact on treatment efficacy in patients with melanoma receiving adjuvant ICI Methods A national multicenter retrospective cohort resected stage III/IV treated PD-1 inhibitors between November 2018 December 2020....